Evaluation of drug efficacy <i>in vivo</i> and <i>in vitro</i> using patient-derived xenograft (PDX)

DOI Web Site

Bibliographic Information

Other Title
  • 患者由来がん組織移植片（PDX）モデルを用いたin vivoおよびin vitroにおける薬効評価

Description

<p>To improve the success rate of anti-cancer drug development, clinically relevant tumor models are needed. Patient-derived xenograft (PDX) tumor, which is generated by direct implantation of human tumor into immunodeficient mice, has been well-accepted as a more clinically relevant model than cell line-derived xenograft (CDX) tumor. </p><p>We have been developing both in vivo and in vitro screening systems for anti-cancer drugs using PDX tumors that had been established in the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN). In this study, we confirmed anti-cancer drug efficacy using PDX in vivo and in vitro. </p><p>In the in vivo study, the PDX tumor was subcutaneously transplanted into immunodeficient mice, and a control group and drug group were set.  Gemcitabine or 5-FU was administered once or twice a week, and observation was carried out until 28 days after starting administration. Anti-cancer effect was evaluated by tumor volume.</p><p>In the in vitro study, three-dimensional culture was performed using dispersed cells derived from PDX tumor.  Drugs were added to the medium and the cell viability was confirmed by ATP assay.</p><p>In both studies, the effect of anti-cancer drug was confirmed, and an evaluation system in vivo and in vitro using PDX could be established.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top